A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

Quinten, Chantal; Martinelli, Francesca; Coens, Corneel; Sprangers, Mirjam A. G.; Ringash, Jolie; Gotay, Carolyn; Bjordal, Kristin; Greimel, Eva; Reeve, Bryce B.; Maringwa, John; Ediebah, Divine E.; Zikos, Efstathios; King, Madeleine; Osoba, David; Taphoorn, Martin J.B.; Flechtner, Henning; Koch, J. Schmucker-Von; Weis, Joachim; Bottomley, Andrew

doi:10.1002/cncr.28382

Cited by 176 publications

(151 citation statements)

References 47 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…A follow-up analysis from this cohort showed the predictive value of physical functioning for survival for most cancer sites, in addition to other QOL domains (for example, physical functioning, emotional functioning, global health status and nausea and vomiting were predictive in breast cancer patients, and physical functioning and pain were predictive in lung cancer patients). 29 We had hypothesized that baseline QOL would mediate survival post allogeneic HCT and we found that PWB was independently significantly associated with overall survival. PWB is a measure of patient-reported symptoms including energy, nausea, and side effects of 'feeling ill. ' We thus hypothesized that QOL would primarily mediate survival through its association with NRM.…”

Section: Discussionmentioning

confidence: 75%

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients

Hamilton

Law

Rybicki

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Quality of life (QOL) is an important outcome for hematopoietic cell transplantation (HCT) recipients. Whether pre-HCT QOL adds prognostic information to patient and disease related risk factors has not been well described. We investigated the association of pre-HCT QOL with relapse, non-relapse mortality (NRM), and overall mortality after allogeneic HCT. From 2003 to 2012, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale instrument was administered before transplantation to 409 first allogeneic HCT recipients. We examined the association of the three outcomes with (1) individual QOL domains, (2) trial outcome index (TOI) and (3) total score. In multivariable models with individual domains, functional well-being (hazard ratio (HR) 0.95, P = 0.025) and additional concerns (HR 1.39, P = 0.002) were associated with reduced risk of relapse, no domain was associated with NRM, and better physical well-being was associated with reduced risk of overall mortality (HR 0.97, P = 0.04). TOI was not associated with relapse or NRM but was associated with reduced risk of overall mortality (HR 0.93, P = 0.05). Total score was not associated with any of the three outcomes. HCT-comorbidity index score was prognostic for greater risk of relapse and mortality but not NRM. QOL assessments, particularly physical functioning and functional well-being, may provide independent prognostic information beyond standard clinical measures in allogeneic HCT recipients. Despite advances in transplantation techniques and supportive care, the morbidity and mortality related to this intensive treatment remain high. Many factors predict survival outcomes after allogeneic HCT, including patient age, comorbidities, donor source, performance status, diagnoses, disease status, and carepartner support. Although several studies have investigated and described QOL after transplantation, including the trajectory of QOL risk factors for QOL impairments and interventions to improve QOL, 13-20 the association of pre-transplantation QOL with recovery and survival after allogeneic HCT has not been well described. We hypothesized that QOL measures before HCT may add to the prognostic information provided by known clinical factors among allogeneic HCT recipients. We therefore undertook this analysis to determine the prognostic impact of pre-transplant QOL scores, as captured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), on post-HCT non-relapse mortality (NRM) and overall mortality.

show abstract

Section: Discussionmentioning

confidence: 75%

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients

Hamilton

Law

Rybicki

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The survival and quality of life of many patients with cancer are negatively affected by treatment-induced side effects, two of which are nausea and vomiting (1)(2)(3). Chemotherapy is thought to induce nausea and vomiting by triggering the release of neurotransmitters from cells lining the gastrointestinal (GI) tract.…”

Section: Introductionmentioning

confidence: 99%

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Zong¹,

Zhang²,

Ji³

et al. 2016

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Background: Few studies have attempted to evaluate the use of antiemetic therapy for chemotherapyinduced nausea and vomiting (CINV) at a national level in China or to assess how treatment regimens adhere to current guidelines. Methods:We searched the China Health Insurance Research Association (CHIRA) Database to identify patients with cancer who were ≥18 years old and received either moderately or highly emetogenic chemotherapy (MEC and HEC, respectively) between 2008 and 2012. Patients' characteristics as well as usage of specific antiemetic regimens were analyzed using descriptive statistics.Results: Of the 14,548 patients included in the study, 6,477 received HEC while 8,071 were treated with MEC. Approximately 89.9% used antiemetics prophylactically to prevent acute CINV and 71.5% for delayed CINV while 9.0% were prescribed antiemetics as rescue therapy. A significantly lower proportion of patients treated with HEC received prophylactic antiemetic therapy for delayed CINV as compared to those treated with MEC (59.4% vs. 81.3%; P<0.001). The HEC group had a slightly lower proportion of patients using a mixed regimen containing a 5-HT3 antagonist to prevent both acute and delayed CINV than the MEC group (P≤0.012); however, a higher proportion received a mixed regimen containing corticosteroids (P≤0.007). Although more than half of the patients in the HEC group took three antiemetics to prevent acute and delayed CINV, these rates were significantly lower than those of the MEC group (both P<0.001).Finally, analysis of the regimens used revealed that there is over-utilization of drugs within the same class of antiemetic.Conclusions: These findings indicate that more attention is needed for treatment of delayed CINV, in terms of both overall use and the components of a typical treatment regimen.

show abstract

“…Nonetheless, other patient-reported symptoms have been more extensively studied and their importance as independent prognostic factors in various cancers, including advanced colorectal cancer, has been confirmed 1,[17][18][19][20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer

et al. 2015

View full text Add to dashboard Cite

Oxana. (2015) Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. Sleep Medicine, 16 (3). pp. 391-398. Permanent WRAP URL:http://wrap.warwick.ac.uk/85120 Copyright and reuse:The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. A note on versions:The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP url' above for details on accessing the published version and note that access may require a subscription.

show abstract

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

Cited by 176 publications

References 47 publications

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients

Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China

Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer

Contact Info

Product

Resources

About